Etripamil Nasal Spray (Cardamyst) for Paroxysmal Supraventricular Tachycardia
Etripamil Nasal Spray (Cardamyst) for Paroxysmal Supraventricular Tachycardia
April 13, 2026 (Issue: 1752)
The FDA has approved Cardamyst (Milestone), a
nasal spray formulation of the nondihydropyridine
calcium channel blocker etripamil, for conversion
of acute symptomatic episodes of paroxysmal
supraventricular tachycardia (PSVT) to sinus rhythm
in...more
- M Rehorn et al. Prevalence and incidence of patients with paroxysmal supraventricular tachycardia in the United States. J Cardiovasc Electrophysiol 2021; 32:2199. doi:10.1111/jce.15109
- RL Page et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2016; 67:e27. doi:10.1016/j.jacc.2015.08.856
- J Brugada et al. 2019 ESC guidelines for the management of paients with supraventricular tachycardia. Eur Heart J 2020; 41:655. doi:10.1093/eurheartj/ehz467
- P Alboni et al. Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia. J Am Coll Cardiol 2001; 37:548. doi:10.1016/s0735-1097(00)01128-1
- SJ Yeh et al. Termination of paroxysmal supraventricular tachycardia with a single oral dose of diltiazem and propranolol. Circulation 1985; 71:104. doi:10.1161/01.cir.71.1.104
- JE Ip et al. Pharmacokinetics and pharmacodynamics of etripamil, an intranasally administered, fast-acting, nondihydropyridine calcium channel blocker. Clin Pharmacol Drug Dev 2024; 13:367. doi:10.1002/cpdd.1383
- BS Stambler et al. Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial. Lancet 2023; 402:118. doi:10.1016/s0140-6736(23)00776-6
- GG Briggs et al. Briggs drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 12th edition. Philadelphia: Lippincott Williams & Wilkins, 2021.
- Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Verapamil. [Updated 2025 Aug 15]. Available at: https://bit.ly/4bu0icl. Accessed March 26, 2026.
- Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. March 5, 2026. Reprinted with permission by First Databank, Inc. All rights reserved. ©2026. www.fdbhealth.com/drug-pricing-policy.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Etripamil Nasal Spray (Cardamyst) for Paroxysmal Supraventricular Tachycardia
Article code: 1752b
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
